Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium.
Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium.
复制标题
通过在化学成分确定的培养基中生长的确定的恶性黑色素瘤细胞株产生黑色素瘤相关抗原。
作者：
D. Chee;A. Boddie;J. Roth;E. Holmes;D. Morton
人恶性黑色素瘤细胞株UCLA-SO-M14（M14）适应于在无血清化学成分确定的培养基（CDM）中生长。通过白细胞迁移抑制（LMI），测定了从CDM生长细胞（M-14-CDM）制备的3 M KCl提取物对黑色素瘤患者、其他癌症患者和正常供体白细胞的抑制作用。白细胞从15至27（56%）黑色素瘤患者测试是LMI阳性。与此相反，18例其他癌症患者中有4例（22%）和30例正常供体中有5例（17%）的白细胞为LMI阳性。14名黑色素瘤患者中的一名患者的白细胞对来自自体肌肉的对照3 M KCl提取物呈LMI阳性。使用来自M14细胞株供体的新鲜活检肿瘤标本的M14-CDM浸提液和3 M KCl浸提液进行比较研究。12名黑色素瘤患者的白细胞中有7名（58%）对M14-CDM提取物呈LMI阳性，但12名患者中只有2名（17%）对自体黑色素瘤组织提取物呈LMI阳性。此外，仅需要100至300 μ g蛋白质的M14-CDM提取物就可以在8名黑素瘤患者中的6名（75%）和5名肺癌患者中的0名中引起迟发性皮肤超敏反应。但在42例中的24例（57%）中，需要500 μ g来自活组织检查的自体黑素瘤组织提取物的蛋白质来产生迟发性皮肤超敏反应。黑色素瘤患者和28例非黑色素瘤癌症患者中的7例（25%）。这些数据表明：（a）M14-CDM细胞在CDM中合成黑素瘤相关抗原（MAA）;（B）3 M KCl提取程序有效地从M14-CDM细胞中除去MAA;（c）M14-CDM细胞是比手术自体黑素瘤样本更有效的MAA来源;和（d）M14-CDM细胞提供标准MAA的连续来源。
A human malignant melanoma cell strain, UCLA-SO-M14 (M14), was adapted to grow in serum-free, chemically defined medium (CDM). The 3 M KCl extract prepared from the CDM-grown cells (M-14-CDM) was assayed against leukocytes from melanoma patients, patients with other cancers, and normal donors by leukocyte migration inhibition (LMI). The leukocytes from 15 to 27 (56%) melanoma patients tested were LMI positive. In contrast, 4 of 18 (22%) other cancer patients and 5 of 30 (17%) normal donors leukocytes were LMI positive. One of 14 melanoma patients' leukocytes were LMI positive for a control 3 M KCI extract from autologous muscle. Comparative studies were performed with the M14-CDM extract and a 3 M KCI extract from a freshly biopsied tumor specimen from the donor of the M14 cell strain. Seven of 12 (58%) melanoma patients' leukocytes were LMI positive to the M14-CDM extract, but only 2 of 12 (17%) were LMI positive to the autologous melanoma tissue extract. Furthermore, only 100 to 300 mug protein of M14-CDM extract were required to educe delayed cutaneous hypersensitivity response in 6 of 8 (75%) melanoma patients and 0 of 5 lung cancer patients, but 500 mug protein from biopsied autologous melanoma tissue extract were needed to produce delayed cutaneous hypersensitivity response in 24 of 42 (57%) melanoma patients and 7 of 28 (25%) nonmelanoma cancer patients. These data suggest: (a) the M14-CDM cells synthesized melanoma-associated antigen(s) (MAA) in CDM; (B) the 3 M KCI extraction procedure effectively removed the MAA from the M14-CDM cells; (c) the M14-CDM cells were a more potent source of MAA than the surgical autologous melanoma specimen; and (d) the M14-CDM cells provided a continuous source of standard MAA.